2-hydroxymethyl-4-ethylphenol | 29922-49-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-hydroxymethyl-4-ethylphenol
• 英文别名: 5-ethyl-2-hydroxy-benzyl alcohol；6-Hydroxy-1-hydroxymethyl-3-aethyl-benzol；2-Hydroxymethyl-4-aethyl-phenol；5-Aethyl-2-hydroxy-benzylalkohol；4-Ethyl-2-(hydroxymethyl)phenol
• CAS: 29922-49-4
• 化学式: C₉H₁₂O₂
• 分子量: 152.193
• InChiKey: UXRVYHCXUCEIKK-UHFFFAOYSA-N

物化性质

• 熔点：
  83 °C
• 沸点：
  295.8±25.0 °C(Predicted)
• 密度：
  1.131±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  40.5
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-hydroxymethyl-4-ethylphenol 在 sodium periodate 、 苄基三乙基氯化铵 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 0.25h， 生成
  参考文献：
  名称：

  通过成对氧化脱芳构化和 N-羟基氨基甲酸酯脱氢实现高度官能化的三环恶嗪酮：受河豚毒素启发的分子多样性

  摘要：

  苯类原则上代表了用于制备取代环己烷的有吸引力且丰富的原料；然而，可用于克服这些构件固有的大量芳烃能量的合成工具限制了可用的产品类型。在本文中，我们通过使用普通氧化剂利用 2-羟甲基苯酚的氧化脱芳构化和同时进行的 N-羟基氨基甲酸酯脱氢，证明了获得迄今为止未知的杂三环结构。成对生成的、相互反应的物质然后参与第二阶段的酰基亚硝基 Diels-Alder 环加成反应。衍生的 [2.2.2]-oxazabicycles 具有四个正交官能团和三个立体中心，其反应化学显示下游产品具有相当大的多样性。

  DOI：

  10.1021/jacs.7b07745
• 作为产物：
  描述：

  4-乙基苯酚 在 sodium tetrahydroborate 、 (C₄H₉)3N 、 四氯化锡 作用下， 以 甲醇 、 水 、 甲苯 为溶剂， 反应 4.0h， 生成 2-hydroxymethyl-4-ethylphenol
  参考文献：
  名称：

  Payne, Peter; Tyman, John H. P.; Mehet, Satinder K., Journal of Chemical Research, 2006, # 6, p. 402 - 405

  摘要：

  DOI：

文献信息

• Water-promoted ortho-selective monohydroxymethylation of phenols in the NaBO₂ system
  作者：Hui-Jing Li、Ying-Ying Wu、Qin-Xi Wu、Rui Wang、Chun-Yang Dai、Zhi-Lun Shen、Cheng-Long Xie、Yan-Chao Wu

  DOI：10.1039/c4ob00228h

  日期：——

  Water-promoted ortho-selective monohydroxymethylation of phenols in the NaBO₂ system generates salicyl alcohols in excellent yields.

  在NaBO2体系中，水促进了酚的ortho-选择性单羟甲基化反应，产生了优良产率的水杨醇。
• Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors
  申请人：Hummersone Marc Geoffrey

  公开号：US20080194546A1

  公开（公告）日：2008-08-14

  There is provided a compound of formula I: wherein: one or two of X 5 , X 6 and X 8 is N, and the others are CH; R 7 is selected from halo, OR O1 , SR S1 , NR N1 R N2 , NR N7a C(═O)R C1 , NR N7b SO 2 R S2a , an optionally substituted C 5-20 heteroaryl group, or an optionally substituted C 5-20 aryl group, where R O1 and R S1 are selected from H, an optionally substituted C 5-20 aryl group, an optionally substituted C 5-20 heteroaryl group, or an optionally substituted C 1-7 alkyl group; R N1 and R N2 are independently selected from H, an optionally substituted C 1-7 alkyl group, an optionally substituted C 5-20 heteroaryl group, an optionally substituted C 5-20 aryl group or R N1 and R N2 together with the nitrogen to which they are bound form a heterocyclic ring containing between 3 and 8 ring atoms; R C1 is selected from H, an optionally substituted C 5-20 aryl group, an optionally substituted C 5-20 heteroaryl group, an optionally substituted C 1-7 alkyl group or NR N8 R N9 , where R N8 and R N9 are independently selected from H, an optionally substituted C 1-7 alkyl group, an optionally substituted C 5-20 heteroaryl group, an optionally substituted C 5-20 aryl group or R N8 and R N9 together with the nitrogen to which they are bound form a heterocyclic ring containing between 3 and 8 ring atoms; R S2a is selected from H, an optionally substituted C 5-20 aryl group, an optionally substituted C 5-20 heteroaryl group, or an optionally substituted C 1-7 alkyl group; R N7a and R N7b are selected from H and a C 1-4 alkyl group; R N3 and R N4 , together with the nitrogen to which they are bound, form a heterocyclic ring containing between 3 and 8 ring atoms; R 2 is selected from H, halo, OR O2 , SR S2b , NR N5 R N6 , an optionally substituted C 5-20 heteroaryl group, and an optionally substituted C 5-20 aryl group, wherein R O2 and R S2b are selected from H, an optionally substituted C 5-20 aryl group, an optionally substituted C 5-20 heteroaryl group, or an optionally substituted C 1-7 alkyl group; R N5 and R N6 are independently selected from H, an optionally substituted C 1-7 alkyl group, an optionally substituted C 5-20 heteroaryl group, and an optionally substituted C 5-20 aryl group, or R N5 and R N6 together with the nitrogen to which they are bound form a heterocyclic ring containing between 3 and 8 ring atoms, or a pharmaceutically acceptable salt thereof, with the proviso that when R 2 is unsubstituted morpholino. R N3 and R N4 together with the nitrogen atom to which they are attached form an unsubstituted morpholino and R 7 is unsubstituted phenyl, and X 5 is CH, then X 6 is not N and X 8 is not CH, or X 6 is not CH and X 8 is not N, and when R 2 is unsubstituted piperidinyl, R N3 and R N4 together with the nitrogen atom to which they are attached form an unsubstituted piperidinyl and R 7 is unsubstituted phenyl, and X 5 is CH, then X 6 is not CH and X is not N. There are also provided processes for the manufacture of a compound of Formula 1, and the use of a compound of Formula 1 as a medicament and in the treatment of cancer.

  提供了一种化合物，其化学式为I：其中：X5、X6和X8中的一个或两个是N，其余为CH；R7选自卤素、ORO1、SRS1、NRN1RN2、NRN7aC（═O）RC1、NRN7bSO2RS2a、可选取代的C5-20杂环芳基基团或可选取代的C5-20芳基基团，其中RO1和RS1选自H、可选取代的C5-20芳基基团、可选取代的C5-20杂环芳基基团或可选取代的C1-7烷基基团；RN1和RN2独立选自H、可选取代的C1-7烷基基团、可选取代的C5-20杂环芳基基团、可选取代的C5-20芳基基团或RN1和RN2与它们所连接的氮原子一起形成含有3至8个环原子的杂环环；RC1选自H、可选取代的C5-20芳基基团、可选取代的C5-20杂环芳基基团、可选取代的C1-7烷基基团或NRN8RN9，其中RN8和RN9独立选自H、可选取代的C1-7烷基基团、可选取代的C5-20杂环芳基基团、可选取代的C5-20芳基基团或RN8和RN9与它们所连接的氮原子一起形成含有3至8个环原子的杂环环；RS2a选自H、可选取代的C5-20芳基基团、可选取代的C5-20杂环芳基基团或可选取代的C1-7烷基基团；RN7a和RN7b选自H和C1-4烷基基团；RN3和RN4与它们所连接的氮原子一起形成含有3至8个环原子的杂环环；R2选自H、卤素、ORO2、SRS2b、NRN5RN6、可选取代的C5-20杂环芳基基团和可选取代的C5-20芳基基团，其中RO2和RS2b选自H、可选取代的C5-20芳基基团、可选取代的C5-20杂环芳基基团或可选取代的C1-7烷基基团；RN5和RN6独立选自H、可选取代的C1-7烷基基团、可选取代的C5-20杂环芳基基团和可选取代的C5-20芳基基团，或RN5和RN6与它们所连接的氮原子一起形成含有3至8个环原子的杂环环，或其药学上可接受的盐，但当R2为未取代的吗啡啶基时，RN3和RN4与它们所连接的氮原子一起形成未取代的吗啡啶基，R7为未取代的苯基，且X5为CH时，X6不是N且X8不是CH，或X6不是CH且X8不是N，当R2为未取代的哌啶基时，RN3和RN4与它们所连接的氮原子一起形成未取代的哌啶基，R7为未取代的苯基，且X5为CH时，X6不是CH且X不是N。还提供了制造化合物I的方法，以及将化合物I用作药物治疗癌症的用途。
• Pyrimidine Sulphonamide Derivatives as Chemokine Receptor Modulators
  申请人：Cheshire David Ranulf

  公开号：US20080096860A1

  公开（公告）日：2008-04-24

  A compound of formula (1), or a pharmaceutically acceptable salt, solvate or in vivo hydrolysable ester thereof and pharmaceutical compositions comprising these, all for use in the treatment of chemokine mediated diseases and disorders.

  公式（1）的化合物，或其药学上可接受的盐，溶剂或体内可水解的酯，以及包含这些化合物的制药组合物，均可用于治疗趋化因子介导的疾病和障碍。
• Applying conjoint analysis in economic evaluations: an application to menorrhagia
  作者：Fernando San Miguel、Mandy Ryan、Emma McIntosh

  DOI：10.1080/000368400322165

  日期：2000.6
• Direct B-Alkyl Suzuki-Miyaura Cross-Coupling of Trialkyl- boranes with Aryl Bromides in the Presence of Unmasked Acidic or Basic Functions and Base-Labile Protections under Mild Non-Aqueous Conditions
  作者：Bing Wang、Hui-Xia Sun、Zhi-Hua Sun、Guo-Qiang Lin

  DOI：10.1002/adsc.200800630

  日期：2009.2

  Abstractmagnified imageAn efficient and chemoselective palladium‐catalyzed direct B‐alkyl Suzuki–Miyaura cross‐coupling of trialkylboranes with diversely functionalized aryl bromides is described. A wide variety of unmasked acidic or basic functions are tolerated. The mild non‐aqueous conditions are compatible with aldehydes, ketones, nitriles, chloro substitution as well as base‐labile phenolic Piv and TBS protecting groups. The anhydrous conditions were found to be advantageous for aryl bromide substrates. A potent CEPT inhibitor was efficiently synthesised using this protocol.